BR112022024929A2 - Derivados de aminopirimidinila - Google Patents

Derivados de aminopirimidinila

Info

Publication number
BR112022024929A2
BR112022024929A2 BR112022024929A BR112022024929A BR112022024929A2 BR 112022024929 A2 BR112022024929 A2 BR 112022024929A2 BR 112022024929 A BR112022024929 A BR 112022024929A BR 112022024929 A BR112022024929 A BR 112022024929A BR 112022024929 A2 BR112022024929 A2 BR 112022024929A2
Authority
BR
Brazil
Prior art keywords
aminopyrimidinyl
derivatives
hydroxy
combinations
compounds
Prior art date
Application number
BR112022024929A
Other languages
English (en)
Inventor
Stephen Gerstenberger Brian
Jiao Wenhua
Singh Lall Manjinder
Lira Ricardo
Edward Schnute Mark
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR112022024929A2 publication Critical patent/BR112022024929A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

DERIVADOS DE AMINOPIRIMIDINILA. A presente invenção refere-se a um composto de fórmula I: ou um sal farmaceuticamente aceitável do mesmo, em que R1 e R2 são cada independentemente hidrogênio ou hidróxi; em que R1 e R2 não são ambos hidróxi. Também são fornecidos métodos de tratamento como inibidores de Janus quinase e composições farmacêuticas contendo os compostos da invenção e combinações dos mesmos com outros agentes terapêuticos.
BR112022024929A 2020-07-02 2021-06-30 Derivados de aminopirimidinila BR112022024929A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063047606P 2020-07-02 2020-07-02
PCT/IB2021/055851 WO2022003583A1 (en) 2020-07-02 2021-06-30 Aminopyrimidinyl derivatives

Publications (1)

Publication Number Publication Date
BR112022024929A2 true BR112022024929A2 (pt) 2023-01-31

Family

ID=76829589

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022024929A BR112022024929A2 (pt) 2020-07-02 2021-06-30 Derivados de aminopirimidinila

Country Status (15)

Country Link
US (1) US11655252B2 (pt)
EP (1) EP4175959A1 (pt)
JP (1) JP2023531992A (pt)
KR (1) KR20230018459A (pt)
CN (1) CN115996930A (pt)
AR (1) AR122860A1 (pt)
AU (1) AU2021301417B2 (pt)
BR (1) BR112022024929A2 (pt)
CA (1) CA3190243A1 (pt)
IL (1) IL299603A (pt)
MX (1) MX2022015986A (pt)
PY (1) PY2154360A (pt)
TW (1) TWI782599B (pt)
UY (1) UY39308A (pt)
WO (1) WO2022003583A1 (pt)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0901786T3 (da) 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
EP2638018A1 (en) * 2010-11-09 2013-09-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors
EP2832734A4 (en) * 2012-03-28 2015-08-26 Takeda Pharmaceutical HETEROCYCLIC COMPOUND
GB201303109D0 (en) * 2013-02-21 2013-04-10 Domainex Ltd Novel pyrimidine compounds
BR112016016397B1 (pt) * 2014-01-24 2021-06-29 Bayer Cropscience Aktiengesellschaft Processo para preparar 1-alquil-3-difluorometil-5- fluoro-1h-pirazol-4-carbaldeídos ou os seus ésteres
NO2721710T3 (pt) * 2014-08-21 2018-03-31
EP3347097B1 (en) * 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
US20210052593A1 (en) * 2018-03-09 2021-02-25 Children's Hospital Medical Center Compositions and Methods for the Treatment of Macrophage Activation Syndrome
CN112142743A (zh) * 2019-06-28 2020-12-29 广州诺诚健华医药科技有限公司 杂环类化合物、其制备方法及其在医药学上的应用

Also Published As

Publication number Publication date
CA3190243A1 (en) 2022-01-06
TW202208371A (zh) 2022-03-01
AU2021301417A1 (en) 2023-01-19
TWI782599B (zh) 2022-11-01
EP4175959A1 (en) 2023-05-10
US11655252B2 (en) 2023-05-23
MX2022015986A (es) 2023-02-01
JP2023531992A (ja) 2023-07-26
PY2154360A (es) 2022-04-20
IL299603A (en) 2023-03-01
US20220002301A1 (en) 2022-01-06
UY39308A (es) 2022-01-31
AU2021301417B2 (en) 2023-09-28
AR122860A1 (es) 2022-10-12
KR20230018459A (ko) 2023-02-07
WO2022003583A1 (en) 2022-01-06
CN115996930A (zh) 2023-04-21

Similar Documents

Publication Publication Date Title
MX2023007192A (es) Inhibidores de prmt5.
JOP20230113A1 (ar) مشتقات ثلاثية الكربوكساميد كمثبطات prmt5
BR112022025037A2 (pt) Compostos antivirais para tratar infecções por coronavírus, picornavírus e norovírus
BR112022010254A2 (pt) Composto heterocíclico contendo oxigênio representado pela fórmula i, método para preparar o composto heterocíclico contendo oxigênio, composto, composição farmacêutica e uso composto heterocíclico contendo oxigênio
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
BR112021009595A2 (pt) Terapia de combinação incluindo um inibidor de krasg12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cânceres
BR112022013593A2 (pt) Inibidores de mek e usos terapêuticos dos mesmos
BR112022000431A2 (pt) Derivados de 2-morfolinopiridina substituídos como inibidores da atr cinase
BR112016015983A2 (pt) Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica
BR112022000019A2 (pt) Composto da fórmula, composição farmacêutica e método de tratamento de câncer
UY37133A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
MX2022007130A (es) Derivados de piperazina sustituidos utiles como activadores de celulas t.
BR112015028501B8 (pt) Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico
BRPI0813244B8 (pt) compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário
BR112015015635A2 (pt) inibidores de quinases de proteínas
BR112022003408A2 (pt) Triazolopirimidinas como inibidores de a2a/a2b
BR112021019817A2 (pt) Compostos de pirrol
BR112021018238A2 (pt) Derivados de azolopiridina macrocíclicos como moduladores de eed e prc2
BR0212435A (pt) Derivados de 3-(4,5,6,7-tetraidroindol-2-ilmetilideno)-2-indolinona como inibidores de cinase
BR112022018067A2 (pt) Aminas de pirrolopirimidina como inibidores de complemento
EA201992090A1 (ru) ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА
BR0313727A (pt) Derivados de isoquinolina como inibidores de metaloproteinase da matriz
BR112022006394A2 (pt) Derivados heterocíclicos, composições farmacêuticas e seu uso no tratamento ou melhora do câncer
BRPI0515991A (pt) derivados de bisariluréia substituìda heterocìclica como inibidores de cinase
BR112023002031A2 (pt) Derivados de espiropiperidinila substituídos por heteroarila e usos farmacêuticos dos mesmos

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: PFIZER INC. (US)

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]